Tuesday, December 2, 2014
Puma Forced to Delay Breast Cancer FDA Submission Due to New Safety Data Requirement
… an approval filing for its breast cancer drug neratinib into 2016 -- … the HER2 protein found in breast cancer. Puma is developing the drug … in patients with metastatic HER2-positive breast cancer.
Puma had expected to file …
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment